Clinica's Medtech Ventures: Issue 4: Vivoxid to tackle worldwide orthopaedic market with bioactive glass
This article was originally published in Clinica
Executive Summary
Company: Vivoxid Specialty area(s): Biomaterials Based in: Turku, Finland Founded in: 2001 No. of employees: 25 Total investment received to date: E7m ($9.6m) from Sitra, Varma Mutual Pension Insurance Company, Sentica Partners
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.